EC
ALNY icon

EcoR1 Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

EcoR1 Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-98,146
Closed -$16.6M – 88
2021
Q4 		$16.6M Buy
+98,146
New +$18.2M 0.53% 30
2017
Q3 		– Sell
-10,425
Closed -$831K – 41
2017
Q2 		$831K Buy
+10,425
New +$666K 0.15% 34

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital's ALNY Position: Q1 2022 in Review

EcoR1 Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 98,146 shares — an estimated $16.6M sold.

EcoR1 Capital first reported a position in ALNY in Q2 2017 and held it in 2 quarters. The position peaked at $16.6M in Q4 2021. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

  • EcoR1 Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • EcoR1 Capital sold 98,146 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $16.6M.
  • EcoR1 Capital first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • EcoR1 Capital's Alnylam Pharmaceuticals position peaked at $16.6M in Q4 2021.
  • 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.